Blueprint Medicines Competitors and Similar CompaniesClear all

Blueprint Medicines's competitors and similar companies include Deciphera Pharmaceuticals and Repare Therapeutics.
Blueprint Medicines
Blueprint Medicines
Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders.
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer.
Repare Therapeutics
Repare Therapeutics
Repare Therapeutics is a company that develops oncology drugs for patients that target specific vulnerabilities of tumor cells.
Founding Date
Founding Date
2011
Founding Date
2003
Founding Date
2016
Type
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Cambridge, US HQ
Amsterdam, NL
Lugano, CH
Zug, CH
Locations
Waltham, US HQ
Lawrence, US
Locations
Montréal, CA HQ
Cambridge, US
Employees
Employees
6552% increase
Employees
35037% increase
Employees
179
Valuation ($)
Valuation ($)
5.3 b
Valuation ($)
2.2 b
Valuation ($)
152.4 m

Financial

Revenue (est.)
Revenue (est.)
$508.8m (FY, 2024)
Revenue (est.)
$163.4m (FY, 2023)
Revenue (est.)
$51.1m (FY, 2023)
Cost of goods
Cost of goods
$20.2m (FY, 2024)
Cost of goods
$3.7m (FY, 2023)
Cost of goods
N/A
Gross profit
Gross profit
$488.7m (FY, 2024)
Gross profit
$159.6m (FY, 2023)
Gross profit
$51.1m (FY, 2023)
Net income
Net income
($67.1m) (FY, 2024)
Net income
($194.9m) (FY, 2023)
Net income
($93.8m) (FY, 2023)

Funding

Total funding raised
Total funding raised
$ 1.7b
Total funding raised
$ 714m
Total funding raised
$ 150.5m
For sources of this data, please see the company profile

View Company Profiles

Deciphera Pharmaceuticals
HQ
Waltham, US
Employees
350↑ 37% increase

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer.

View company
Repare Therapeutics
HQ
Montréal, CA
Employees
179

Repare Therapeutics is a company that develops oncology drugs for patients that target specific vulnerabilities of tumor cells.

View company